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ABSTRACT
Objective: To update the Cochrane review comparing
the effects of home-based and supervised centre-based
cardiac rehabilitation (CR) on mortality and morbidity,
quality of life, and modifiable cardiac risk factors in
patients with heart disease.
Methods: Systematic review and meta-analysis. The
Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, EMBASE, PsycINFO and
CINAHL were searched up to October 2014, without
language restriction. Randomised trials comparing
home-based and centre-based CR programmes in
adults with myocardial infarction, angina, heart failure
or who had undergone coronary revascularisation were
included.
Results: 17 studies with 2172 patients were included.
No difference was seen between home-based and
centre-based CR in terms of: mortality (relative risk
(RR) 0.79, 95% CI 0.43 to 1.47); cardiac events;
exercise capacity (mean difference (MD) −0.10, −0.29
to 0.08); total cholesterol (MD 0.07 mmol/L, −0.24 to
0.11); low-density lipoprotein cholesterol (MD
−0.06 mmol/L, −0.27 to 0.15); triglycerides (MD
−0.16 mmol/L, −0.38 to 0.07); systolic blood pressure
(MD 0.2 mm Hg, −3.4 to 3.8); smoking (RR 0.98,
0.79 to 1.21); health-related quality of life and
healthcare costs. Lower high-density lipoprotein
cholesterol (MD −0.07 mmol/L, −0.11 to −0.03,
p=0.001) and lower diastolic blood pressure (MD
−1.9 mm Hg, −0.8 to −3.0, p=0.009) were observed
in centre-based participants. Home-based CR was
associated with slightly higher adherence (RR 1.04,
95% CI 1.01 to 1.07).
Conclusions: Home-based and centre-based CR
provide similar benefits in terms of clinical and health-
related quality of life outcomes at equivalent cost for
those with heart failure and following myocardial
infarction and revascularisation.
BACKGROUND
Mortality from coronary heart disease
(CHD) in developed nations has fallen over
the past three decades; however, CHD still
accounts for around 20% of deaths in
Europe.1 In the UK, around 110 000 men
and 65 000 women are admitted with acute
coronary syndrome every year and it is esti-
mated that there are 2.3 million people
living with CHD.2
Cardiac rehabilitation (CR) is offered to
individuals after cardiac events in order to
facilitate recovery and prevent relapse by
optimising cardiovascular risk reduction, fos-
tering healthy behaviours and compliance to
these behaviours, and promoting an active
lifestyle.3 While a central component is exer-
cise training,4 5 it is recommended that CR
programmes provide lifestyle education on
CHD risk factor management plus counsel-
ling and psychological support—so-called
‘comprehensive CR’.6 7 Such programmes
are designed to limit the physiological and
psychological effects of cardiac illness,
reduce the risk for sudden death or reinfarc-
tion following myocardial infarction (MI),
control cardiac symptoms, stabilise or reverse
the atherosclerotic process, and enhance the
psychosocial and vocational status of selected
patients (eg, by improving functional cap-
acity to support early return to work7).
Recent Cochrane reviews demonstrate that
CR improves health-related quality of life
(HRQoL) and reduces hospital admissions
compared with usual care in various patient
groups including those with MI, heart failure
and following percutaneous coronary interven-
tion and coronary artery bypass graft.8 9
National and international professional guide-
lines including the National Institute for
Health and Care Excellence (NICE) in the
UK, the American Heart Association/
American College of Cardiology, and the
European Society of Cardiology recommend
CR as an effective and safe intervention in the
management of CHD and heart failure.10–15
Despite these apparent beneﬁts and
recommendations, participation in CR in the
UK and abroad remains suboptimal, particu-
larly for heart failure.16 17 A 2012 UK-based
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survey found that only 16% of CR centres provided a
programme speciﬁcally designed for people with heart
failure; commonly cited reasons for the lack of provision
of CR were a lack of resources and exclusion from com-
missioning agreements.16 Two main reasons given by
patients for failing to take part in CR are difﬁculties with
regular attendance at their local hospital and reluctance
to join group-based classes.18
Home-based rehabilitation programmes have been
introduced as an alternative to the conventional centre-
based CR to widen access and participation. For
example, the Heart Manual (developed by National
Health Service (NHS) Lothian) is a self-help manual
supported by a trained professional, which is designed
to assist in recovery and improve patients’ understanding
and management of their condition following MI, and is
now widely used in the UK, Italy, Canada, Australia and
New Zealand.19 20
While the previous Cochrane review found home-
based and centre-based CR programmes to be equally
effective in improving participant outcomes,21 22 the
majority of evidence was in low-risk patients following MI
or revascularisation. We are aware of a number of rando-
mised head-to-head trials of centre-based versus home-
based CR in heart failure that have been published since
the previous review.23–25
The aim of this study was to update the previous
(2010) Cochrane systematic review and meta-analysis of
the randomised controlled trial evidence comparing
home-based and centre-based CR.
METHODS
We conducted and reported this systematic review in
accordance with the PRISMA (Preferred Reporting Items
for Systematic Reviews and Meta-Analyses) statement.26
Search methods for identification of studies
The search strategy was designed in accordance with the
previous Cochrane review and used both controlled
vocabulary (eg, Medical Subject Headings (MeSH)) and
key words (‘heart disease and (synonym)’ and ‘rehabili-
tation or exercise or (synonym)’) combined with a ran-
domised controlled trial ﬁlter.21 The list of studies was
updated with electronic searches of the Cochrane
Central Register of Controlled Trials (CENTRAL),
MEDLINE, EMBASE, PsycINFO and CINAHL plus (see
online supplementary material ﬁle, eg). Databases were
searched from January 2008 (end date of previous
review) to October 2014, with no language or other
restrictions. Trial registers (controlled-trials.com and
clinicaltrials.gov) were also checked, in addition to
reference lists of all eligible studies and other published
systematic reviews.
Study selection
We included randomised trials (individual or cluster)
directly comparing home-based versus centre-based CR.
The study population included adults with MI, angina
pectoris or heart failure, or who had undergone coron-
ary revascularisation (coronary artery bypass grafting,
percutaneous transluminal coronary angioplasty or cor-
onary artery stenting).
Home-based CR was deﬁned as a structured pro-
gramme with clear objectives for the participants, includ-
ing monitoring, follow-up visits, letters or telephone calls
from staff or at least self-monitoring diaries.27 Centre-
based CR was a supervised group-based programme
undertaken in a hospital or community setting (eg,
gym or sports centre). We included exercise-only and
comprehensive CR programmes.
Studies with one or more of the following outcome mea-
sures were included: mortality (cardiac and overall); mor-
bidity (reinfarction, revascularisation or cardiac-related
hospitalisation); exercise capacity; modiﬁable coronary risk
factors (ie, smoking, blood lipid levels and blood pres-
sure); HRQoL; adverse events (withdrawal from the trial
or exercise programme); health service use or costs; adher-
ence to CR.
Selection of studies involved the initial screening of
titles and abstracts, followed by an assessment of the full-
text reports of all potentially relevant trials. Two authors
(RST, SGD or RJN) independently assessed trials for
inclusion and where there was a disagreement, the
opinion of a third author (RST, SGD or RJN) was sought.
Data extraction and risk of bias assessment
The following information categories were extracted:
study design, participants (baseline characteristics), details
of the intervention (including type, frequency, duration
and intensity of exercise training and nature of
co-interventions), length of follow-up and outcome
results. We assessed study risk of bias using the Cochrane
standard criteria28 (random sequence generation and allo-
cation concealment, dropouts and withdrawals, outcome
blinding, and selective reporting) and also balance of
groups at baseline and use of intention-to-treat analysis.
Data extraction and risk of bias assessment was carried out
by a single reviewer (RJN) and checked by a second
reviewer (SGD or RST). Where necessary, authors of
included studies were contacted for further information.
This included clariﬁcation of issues of study design to
inform risk of bias assessment and outcomes (eg, missing
SDs).
Data analysis
Data were analysed in accordance with the Cochrane
Handbook.28 For dichotomous variables, relative risks
(RRs) and 95% CIs were calculated for each outcome,
and for continuous variables, mean differences (MDs)
and 95% CIs were calculated. Where differences between
groups for each individual trial were not reported, we
calculated p values for the differences.
We explored heterogeneity among the included
studies qualitatively (by comparing the study character-
istics) and quantitatively (using the χ2 test of
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heterogeneity and I2 statistic). Where appropriate, an
overall estimate of treatment effect was obtained by com-
bining the results from included studies for each
outcome. We employed a random-effects model where
there was formal evidence of statistical heterogeneity
(I2>50%). For outcomes with lower levels of statistical
heterogeneity, we applied both ﬁxed and random
models, reporting ﬁxed-effects results unless there was a
difference in statistical inference, where we reported the
most conservative random-effects model.
Given the variety of outcome measures reported for
exercise capacity, to allow us to pool ﬁndings across
studies, between-group results for each study were
expressed as a standardised MD (SMD). Miller et al29
included subgroups by duration of the intervention (11
or 26 weeks) and Gordon et al30 compared two home-
based exercise groups with a centre-based programme.
For these two studies, outcome results were reported
separately for each comparison. Given the small number
of studies, it was not possible to assess potential small
study effects and publication bias using funnel plots and
Egger tests31 with the exception of the outcome of exer-
cise capacity. We undertook two subgroup analyses for
exercise capacity: (1) comparison of trials of patients
with heart failure versus other post-MI/revascularisation
and (2) comparison of trials published before the year
2000 vs 2000 or later (to assess the impact of older trials
in relation to advancement of medical technology, medi-
cations and interventional cardiology). Analyses were
conducted using RevMan V.5.2.
RESULTS
Study selection
The previous Cochrane review provided 12 included
studies (22 publications; JM Bell. A comparison of a
multi-disciplinary home based cardiac rehabilitation pro-
gramme with comprehensive conventional rehabilitation
in post-myocardial infarction patients. [Thesis submitted
to the University of London for the degree of Doctor of
Philosophy]. 1998).29 30 32–40 Our updated searches pro-
duced a total of 12 949 titles from which an additional
ﬁve studies (six publications) were included.23–25 41 42
Outcomes of one previously included trial with a longer
follow-up (18 months and 6 years postrandomisation)
were also identiﬁed.32 43 The study selection process is
summarised in ﬁgure 1. Excluded studies and reasons for
exclusion are shown in online supplementary table A.
The 17 studies of home-based versus centre-based CR
included a total of 2172 patients in 10 countries from
across four continents (see table 1). Most studies reported
outcomes up to 12 months postrandomisation; three
studies also reported a longer term follow-up.32 36 38
The CR programmes differed considerably between
studies in terms of duration (range 1.5–6 months),
frequency (one to ﬁve sessions per week) and length
(20–60 min per session). Eleven studies compared com-
prehensive programmes (ie, exercise plus education and/
or psychological management) while six reported only an
exercise intervention.23 24 29 35 37 40 Most programmes
used individually tailored exercise prescriptions, making
it difﬁcult to precisely quantify the amount of exercise
undertaken. Almost all home-based programmes were
based on walking with intermittent support from a nurse
or exercise specialist, while centre-based programmes typ-
ically provided a supervised cycle and treadmill exercise
(see online supplementary table B).
Of the 13 studies that recruited patients following acute
MI or coronary revascularisation, 12 of these included
patients classed as ‘low’ or ‘moderate’ risk as deﬁned by
the American Association of Cardiovascular and
Pulmonary Rehabilitation (AACVPR) guidelines for CR
Figure 1 Summary of study selection process.RCT, randomised controlled trial.
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Table 1 Summary of included studies
Study
Participants
(number and
diagnosis) Interventions Outcomes Follow-up Subgroup analyses
Country/
setting
Arthur et al32 242 post-CABG
surgery
Home-based vs
centre-based
Primary: exercise capacity (METs).
Secondary: HRQoL (SF-36), cardiac
morbidity, mortality
6 and 18 months and
6 years
postrandomisation
None Canada,
single
centre
Bell ( JM Bell.
Thesis submitted
to the University
of London for the
degree of Doctor
of Philosophy.
1998)
252 post-MI Home-based
(Heart Manual) vs
centre-based
Primary: exercise capacity (METs)
Secondary: total cholesterol, systolic
blood pressure, HRQoL (NHP),
smoking, mortality, readmission rate,
use of primary care services
16 and 48 weeks
postrandomisation
(20 and 50 weeks
post-MI)
None UK, 5
district
hospitals
Carlson et al33 80 coronary artery
bypass, angioplasty,
MI, angiographically
confirmed CHD
Home-based vs
centre-based
Primary: peak functional capacity
(METs), LDL cholesterol
Secondary: total cholesterol, HDL
cholesterol, triglycerides, blood
pressure, cardiovascular medications,
costs, adherence (exercise sessions
attended)
6 months
postrandomisation
None USA,
single
hospital
centre
Cowie et al23 60 NYHA class II/III
patients with post-HF
Home-based vs
centre-based vs
usual care control
Exercise capacity (shuttle walk test),
HFQoL (SF-36 and MLHFQ)*
8 weeks None UK, single
centre
Dalal et al34 104 post-MI Home-based
(Heart Manual) vs
centre-based
Primary: quality of life (MacNew
questionnaire), total cholesterol
Secondary: exercise capacity (METs),
self-reported smoking, cardiovascular
morbidity, mortality, secondary
prevention medication use
9 months
postrandomisation
None UK, single
centre
Daskapan et al35 29 patients with HF Home-based vs
centre-based
Exercise capacity (mL/kg/min), resting
blood pressure, systolic and diastolic
blood pressure, adherence, dropouts,
mortality*
12 weeks
postrandomisation
None Turkey,
single
centre
Gordon et al30 155 coronary artery
disease (MI and/or
CABG and/or PTCA
and/or chronic stable
angina)
Supervised home
vs community
home vs
centre-based
Maximal oxygen uptake, blood
pressure, fasting serum lipids,
self-reported smoking status,
rehospitalisation, adherence
(completion of appointments)*
12 weeks
postrandomisation
Changes reported for all
patients and for patients
with baseline values
defined as abnormal
USA,
single
centre
Continued
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Table 1 Continued
Study
Participants
(number and
diagnosis) Interventions Outcomes Follow-up Subgroup analyses
Country/
setting
Jolly et al36 525 patients with
post-MI, post-PTCA
and post-CABG
Home-based
(Heart Manual) vs
centre-based
Primary: serum cholesterol, total
cholesterol, HDL cholesterol, blood
pressure, exercise capacity (ISWT),
smoking (cotinine-validated)
Secondary: quality of life (EQ-5D),
health service usage (hospital
readmissions, primary care visits,
medication), mortality, cardiovascular
events, costs
6, 12 and 24 months Yes—‘interaction terms
between these factors
(diagnosis (MI/
revascularisation), age, sex
and ethnicity) and
rehabilitation setting were
included to investigate
possible differences in
treatment effect between
subgroups of patients’.
UK, 4
hospital
centres
Karapolat et al24 74 patients with HF Home-based vs
centre-based
Exercise capacity, quality of life
(SF-36)*
8 weeks None Turkey,
single
centre
Kassaian et al37 125 patients with
post-MI and/or
post-CABG
Home-based vs
centre-based
Systolic and diastolic blood pressure,
heart rate (all resting and submaximal),
functional capacity (METs), BMI,
cholesterol (total, LDL, HDL,
triglyceride)*
12 weeks
postrandomisation
Comparison of functional
capacity, submaximal
systolic blood pressure,
diastolic blood pressure,
and heart rate in patients
with left ventricular
dysfunction vs good
function
Iran, single
centre
Marchionni
et al38
180 patients with
post-MI
Home-based vs
centre-based
Primary: TWC
Secondary: HRQoL (SIP), mortality,
morbidity (cardiovascular events),
healthcare usage (medical visits,
rehospitalisations), costs, adherence
(number of completed training
sessions)
2, 8 and 14 months
postrandomisation
Subgroup analysis by age
(years)—middle-aged (45–
65), old (65–75), very old
(>75)
Italy, single
hospital
centre
Miller et al29 127 patients with
post-MI
Home-based vs
centre-based
Exercise capacity, mortality,
cardiovascular morbidity*
23 weeks
postrandomisation
Results reported according
to 2 subgroups—brief vs
extended exercise training
USA,
single
hospital
centre
Moholdt et al41 30 patients with
post-CABG
Home-based vs
centre-based
(residential
rehabilitation)
Primary: peak oxygen consumption
Secondary: HRQoL, cholesterol (total,
HDL and triglycerides)
6 months
postrandomisation
None Norway,
single
hospital
centre
Oerkild et al42 75 coronary heart
disease (acute MI,
PTCA or CABG)
Home-based vs
centre-based
Primary: exercise capacity (VO2 and
6MWT)
Secondary: systolic and diastolic blood
pressure, cholesterol (total, HDL and
LDL), smoking, HRQoL (SF-12)
3 and 12 months None Denmark,
single
centre
Continued
Buckingham
SA,Taylor
RS,Jolly
K,etal.Open
Heart2016;3:e000463.doi:10.1136/openhrt-2016-000463
5
M
e
ta
-a
n
a
ly
s
is
by copyright.
 on December 2, 2019 at University of Glasgow. Protected http://openheart.bmj.com/ Open Heart: first published as 10.1136/openhrt-2016-000463 on 14 September 2016. Downloaded from 
an
d
secon
dary
prevention
program
m
es, 44
excludin
g
those
w
ith
signiﬁcant
arrhythm
ias
or
com
orbidities.
T
he
only
exception
w
as
the
study
by
O
erkild
et
al 42
w
h
ere
classiﬁ
ca-
tion
w
as
not
possible
due
to
lack
of
in
form
ation.
Four
studies
included
th
ose
w
ith
N
ew
York
H
eart
A
ssociation
(N
YH
A
)
class
II
or
III
heart
failure
(n=315). 23
–25
35
Risk
ofbias
Several
studies
did
n
ot
report
sufﬁ
cien
t
detail
to
fully
assess
th
eir
poten
tial
risk
of
bias
(see
ﬁ
gure
2).
D
etails
of
selection
bias
(ran
dom
allocation
sequen
ce
gen
er-
ation
an
d
con
cealm
en
t)
w
ere
in
particular
poorly
Table 1 Continued
Study
Participants
(number and
diagnosis) Interventions Outcomes Follow-up Subgroup analyses
Country/
setting
Piotrowicz et al25 152 patients with HF
(NYHA class II and
III)
Home-based
(telemonitored) vs
centre-based
(outpatient)
Exercise capacity (6MWT), quality of
life (SF-36), mortality, hospitalisation*
8 weeks None Poland,
single
centre
Sparks et al39 20 post-MI, PTCA or
CABG
Home-based vs
centre-based
Exercise capacity (peak VO2 max),
adherence (compliance with exercise),
safety (dropout)*
12 weeks
postrandomisation
None USA,
single
hospital
centre
Wu et al40 36 patients with
post-CABG
Home-based vs
centre-based
Exercise capacity (METs)* 12 weeks
postrandomisation
None Taiwan
(China),
single
centre
*Primary and secondary outcomes not distinguished.
6MWT, 6 min walk test; BMI, body mass index; CABG, coronary artery bypass graft; CHD, coronary heart disease; HDL, high-density lipoprotein; HF, heart failure; HRQoL, health-related quality
of life; LDL, low-density lipoprotein; MI, myocardial infarction; MET, metabolic equivalent; MLHFQ, Minnesota Living with Heart Failure Questionnaire; NHP, Nottingham Health Profile; NYHA,
New York Heart Association; PTCA, percutaneous transluminal coronary angioplasty; SF-12, 12-item Short Form Health Survey; SF-36, 36-item Short Form Health Survey SIP, Sickness Impact
Profile; TWC, total work capacity.
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reported. However, only two studies presented objective
evidence of imbalances in baseline patient character-
istics.23 32 Given the nature of the CR intervention, it is
not possible to blind the patients or clinicians to group
allocation; in such situations, blinding outcome assessors
to knowledge of allocation is probably of greater import-
ance. Only seven studies stated that they took measures
to blind outcome assessment ( JM Bell. Thesis submitted
to the University of London for the degree of Doctor of
Philosophy. 1998).23 32 34 36 38 40 Although the type of
analysis was often not stated, all studies appeared to
undertake an intention-to-treat analysis (ie, groups were
compared according to initial random allocation). Loss
to follow-up or dropout appeared to vary considerably
across studies and was often asymmetric between home-
based and centre-based groups. Although it was difﬁcult
to quantify the precise level of CR intervention delivered
(due to the individually tailored nature of many pro-
grammes), the intensity of the rehabilitation programme
seemed to differ substantially between the home-based
and centre-based arms. The majority of trials were
judged to be of low risk of bias in terms of selective
reporting and whether groups received the same
co-interventions.
Effects of interventions
Clinical events: mortality and morbidity
All-cause mortality up to 1 year of follow-up was reported
in 8 of the 17 studies ( JM Bell. Thesis submitted to the
University of London for the degree of Doctor of
Philosophy. 1998).25 29 34–36 41 42 A pooled analysis of
these studies (excluding Miller et al,29 who reported no
deaths) found no difference in mortality at 3–12 months
of follow-up between the home-based and centre-based
CR groups (see online supplementary ﬁgure A). The
study of Jolly et al36 found no signiﬁcant between-group
difference at 24 months.
Only four studies reported cardiac events. Dalal et al34
and Jolly et al36 found no signiﬁcant difference in coron-
ary revascularisation or recurrent MI events between
home-based and centre-based CR, and Piotrowicz et al25
reported no heart failure-related admissions in either
group. Oerkild et al42 did not report numbers of events
but stated that there were no between-group differences
in the number and length of admissions and adverse
events including MI, progressive angina, decompensated
congestive heart failure, severe bleeding, new malignant
disease and performance of percutaneous coronary
intervention. In the 6-year follow-up of the study by
Arthur et al,32 43 the total number of hospitalisations
(cardiac and non-cardiac) was greater in centre-based
patients with CR than in the home-based group (79 vs
42, p<0.0001).
Exercise capacity
All 17 included studies reported on exercise capacity in
the short term (≤12 months’ follow-up) and 3 reported
longer term data (>12 months).32 36 38 Measures of
exercise capacity included peak oxygen uptake, walking
distance and workload on a static cycle.
Pooled analysis of all studies showed no difference in
short-term exercise capacity between the home-based
and centre-based CR (random-effects SMD −0.10, 95%
CI −0.29 to 0.08, I2 72%; see table 2 and ﬁgure 3A).
Similarly, pooled analysis of the studies with >12 months’
follow-up showed that there was no evidence of an
overall difference in exercise capacity between the two
groups in the longer term (ﬁxed-effects SMD 0.11, 95%
CI −0.01 to 0.23, I2 0%; see table 2 and ﬁgure 3B).
Arthur et al32 found that mean peak oxygen consump-
tion at 6-year follow-up was higher (p=0.01) in the
home-based CR group (1543 mL/min) than for those
who received centre-based CR (1412 mL/min).
There was no evidence of subgroup difference in the
difference in exercise capacity between home-based and
centre-based CR comparing two groups of trials: (1)
trials in heart failure versus trials in post-MI/revasculari-
sation (subgroup p=0.74); (2) trials published before
2000 versus trials in 2000 or later (subgroup p=0.59).
Modifiable cardiovascular risk factors
Eight trials assessed systolic and diastolic blood pres-
sure30 33–37 42 or systolic blood pressure alone ( JM Bell.
Thesis submitted to the University of London for the
degree of Doctor of Philosophy. 1998), with absolute
values at follow-up reported by all but two studies30 42
which reported change from baseline instead. Pooled
analysis showed no difference in systolic blood pressure
between home-based and centre-based patients with CR
at follow-up (random-effects MD 0.2 mm Hg, 95% CI
−3.4 to 3.8, I2 65%; see table 2, online supplementary
ﬁgure B). Diastolic blood pressure was slightly lower
following centre-based CR compared with home-based
CR (ﬁxed-effects MD<−1.9 mm Hg, 95% CI −0.8 to
−3.0, I2 37%; p=0.009; see table 2, online supplementary
ﬁgure C). At 24 months’ follow-up, Jolly et al36 reported
no difference in either systolic (MD 0.85 mm Hg, 95%
CI −2.5 to 4.2) or diastolic (MD 0.8 mm Hg, 95% CI
−1.1 to 2.6) blood pressure between the home-based
and centre-based groups.
Of the eight trials reporting data on blood lipids, all
reported total cholesterol values ( JM Bell. Thesis sub-
mitted to the University of London for the degree of
Doctor of Philosophy. 1998),30 33 34 36 37 41 42 six
reported high-density lipoprotein (HDL) concentra-
tions30 33 36 37 41 42 and four reported low-density lipo-
protein (LDL) cholesterol and triglycerides.30 33 37 42
Meta-analysis found no evidence of a difference between
the home-based and centre-based groups in terms of
total cholesterol (random-effects MD −0.07 mmol/L,
95% CI −0.24 to 0.11, I2 62%), LDL (random-effects
MD −0.06 mmol/L, 95% CI −0.27 to 0.15, I2 62%) or
triglyceride (random-effects MD −0.16 mmol/L, 95% CI
−0.38 to 0.07, I2 47%) concentrations at 3–12 months’
follow-up (see table 2, online supplementary ﬁgures D, F
and G). There was some evidence of a lower HDL
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concentration following centre-based CR
(random-effects MD −0.07 mmol/L, 95% CI −0.03 to
−0.11, I2 43%; p=0.001; see table 2, online supplemen-
tary ﬁgure E), but the difference in HDL level was not
sustained at 24 months’ follow-up.36
A consistent reduction in self-reported smoking behav-
iour was found in the ﬁve studies that reported this
outcome for the home-based and centre-based CR arms
( JM Bell. Thesis submitted to the University of London
for the degree of Doctor of Philosophy. 1998).30 34 36 42
The proportion of smokers at follow-up in the centre-
based group was similar to that in the home-based group
after 3–12 months (ﬁxed-effects RR 0.98, 95% CI 0.79 to
1.21, I2 0%; see table 2, online supplementary ﬁgure H)
and 24 months (RR=1.16, 95% CI 0.58 to 33.3).36
Health-related quality of life
Pooling of HRQoL outcomes was considered inappropri-
ate due to the wide variation of measures used and
instead results were compared across studies and
tabulated (see table 3). Ten studies reported validated
HRQoL measures including four generic measures
(EQ-5D, Nottingham Health Proﬁle, 36-item Short Form
Health Survey (SF-36) and Sickness Impact Proﬁle) and
one disease-speciﬁc instrument (MacNew). From indi-
vidual ﬁndings, there was no strong evidence of differ-
ences in overall HRQoL outcomes or domain scores at
follow-up between home-based and centre-based CR. All
studies reported improvements in HRQoL from baseline
to follow-up, with the exception of two studies that used
the EQ-5D where there were no changes in either the
home-based or centre-based groups.34 36
Withdrawals and adherence
There was inconsistent reporting of dropout rates from
the intervention, and reasons for withdrawal were often
unclear. Using the number of completers (ie, the
number of patients with outcome data at follow-up), we
found some evidence of a small increase in the comple-
tion rate in the home-based compared with the centre-
Table 2 Summary of the effects of home-based versus centre-based cardiac rehabilitation
Heterogeneity
Outcome or
subgroup
Number of
studies
Number of
participants
Summary estimate
and model
Effect estimate
(95% CI) with p values
where significant χ2 d.f. p Value I2 (%)
Exercise capacity
≤12-month
follow-up
19 1876 Standard mean
difference,
random-effects model
−0.10 (−0.29 to 0.08) 63.30 18 <0.00001 72
12–24-month
follow-up
3 1074 Standard mean
difference,
fixed-effects model
0.11 (−0.01 to 0.23) 0.97 2 0.62 0
Blood pressure (mm Hg) at 3–12-month follow-up
Systolic 9 1117 Mean difference,
random-effects model
0.19 (−3.37 to 3.75) 23.07 8 0.003 65
Diastolic 8 991 Mean difference,
fixed-effects model
−1.86 (−2.95 to −0.76)
lower in centre-based
group (p=0.009)
11.12 7 0.13 37
Cholesterol (mmol/L) at 3–12-month follow-up
Total 9 1109 Mean difference,
random-effects model
−0.07 (−0.24 to 0.11) 20.98 8 0.007 62
HDL 7 883 Mean difference,
fixed-effects model
−0.07 (−0.11 to −0.03)
lower in centre-based
group (p=0.001)
10.49 6 0.11 43
LDL 5 388 Mean difference,
random-effects model
−0.06 (−0.27 to 0.15) 10.60 4 0.03 62
Triglycerides 5 354 Mean difference,
random-effects model
−0.16 (−0.38 to 0.07) 7.59 4 0.11 47
Smoking (3–
12 months)
6 986 Relative risk,
fixed-effects model
0.98 (0.79 to 1.21) 4.48 5 0.48 0
Completers 18 1984 Risk ratio, fixed-effects
model
1.04 (1.01 to 1.07)
higher completion in
home-based group
(p=0.009)
30.26 17 0.02 44
Mortality 7 1166 Relative risk,
fixed-effects model
0.79 (0.43 to 1.47) 1.60 5 0.90 0
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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based programmes (ﬁxed-effects RR 1.04, 95% CI 1.01
to 1.07, I2 44%; p=0.009).
All except four trials ( JM Bell. Thesis submitted to
the University of London for the degree of Doctor of
Philosophy. 1998)35 37 40 reported adherence to the
rehabilitation programme for the duration of the
study. Substantial variation in the deﬁnition and mea-
sures of adherence was seen across studies, so results
were not pooled. Seven studies23 24 29 30 33 34 36
reported no signiﬁcant difference in adherence
between the home-based and centre-based rehabilita-
tion groups, whereas three studies found evidence of
higher adherence in patients undertaking home-based
CR25 32 38 (see online supplementary table C and
ﬁgure I).
Healthcare costs and usage
Costs of the intervention in home-based and centre-
based settings were reported by four studies and are
shown in table 4. In three of the four studies, health-
care costs associated with CR were lower for the home-
based than the centre-based programmes,33 34 38 but
only signiﬁcantly lower in one study.34 Jolly et al36
found home-based CR to be more expensive than
centre-based CR. However, when patients’ costs were
included, no signiﬁcant difference in overall costs
between home-based and centre-based interventions
was seen.
No signiﬁcant differences were observed between the
home-based and centre-based groups in terms of health-
care resource use. Eight studies reported measures of
healthcare usage including hospital readmissions,
primary care consultations and use of secondary care
medication (see table 5).
Small study bias
There was no evidence of funnel plot asymmetry for
exercise capacity (Egger test p=0.71).
DISCUSSION
We conducted an updated systematic review and meta-
analysis comparing the effects of home-based and super-
vised centre-based CR. Our study shows no consistent
evidence to support differences in patient outcomes for
those receiving home-based or centre-based rehabilita-
tion in either the short term (≤12 months) or longer
term (>12 months). Outcomes considered included
exercise capacity, modiﬁable risk factors (blood pressure,
blood lipid concentrations and smoking), HRQoL and
cardiac events (mortality, coronary revascularisation and
hospital readmissions).
The ﬁndings of this updated review are in agreement
with those of the previous Cochrane review comparing
home-based versus centre-based rehabilitation.21
However, importantly, this review now includes data
from four trials in 315 patients with heart failure,23–25 35
supplementing the evidence base in the previous review
that was largely in patients following MI and coronary
revascularisation. Our results are consistent with the
body of evidence that shows centre-based and home-
based delivered disease management to provide similar
beneﬁts to cardiac populations. For example, the recent
WHICH? trial conducted in Australia indicated that a
home-based heart failure management programme was
equally effective in terms of outcome (improved HRQoL
Figure 3 (A) Exercise capacity with home-based and centre-based CR at ≤12 months’ follow-up. (B) Exercise capacity with
home-based and centre-based CR at 12–24 months’ follow-up. CR, cardiac rehabilitation.
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Table 3 Comparison of HRQoL outcomes at follow-up for home-based and centre-based cardiac rehabilitation
Trial
Author (year) Follow-up HRQoL measure
Outcome values at follow-up or mean
difference (95% CI)
Mean (SD)
Home vs centre, between group p value
Between-group
difference
Bell (1998) 10.5 months Nottingham Health
Profile
Energy 18.6 (28.4) vs 17.3 (30.7) p=0.78* Home=centre
Pain 6.6 (15.3) vs 7.4 (15.5) p=0.74* Home=centre
Emotional reactions 6.6 (15.3) vs 7.4 (15.5) p=0.74* Home=centre
Sleep 6.6 (15.3) vs 16.9 (22.8) p=0.0007* Home<centre
Social isolation 3.7 (13.6) vs 6.7 (15.0) p=0.18* Home=centre
Physical mobility 6.9 (13.5) vs 9.1 (15.9) p=0.33* Home=centre
Arthur et al (2002)/
Smith et al (2004)60
6 months SF-36 PCS 51.2 (6.4) vs 48.6 (7.1) p=0.003* Home>centre
MCS 53.5 (6.4) vs 52.0 (8.1) p=0.13* Home=centre
18 months SF-36 PCS 48.3 (11.7) vs 47.6 (11.7) p=0.67* Home=Centre
MCS 53.0 (10.9) vs 50.2 (10.9) p=0.07* Home=centre
Cowie et al (2012) 3 months SF-36 PCS 34.01 (11.04) vs 31.33 (7.97) p=0.82 Home=centre
MCS 44.44 (12.23) vs 48.25 (11.21) p=0.04 Home<centre
MLWHF total 37 (NR) vs 32 (NR) p=0.18 Home=centre
Physical 21 (NR) vs 19 (NR) p=0.31 Home=centre
Emotional 7 (NR) vs 7 (NR) p=0.13 Home=centre
Marchionni et al
(2003)
2 months Sickness Impact
Profile
2.83 (14.5) vs 4.71 (11.1) p=0.09* Home=centre
8 months 2.83 (14.5) vs 3.40 (11.1) p=0.61* Home=centre
14 months 2.00 (8.3) vs 3.70 (11.8) p=0.06* Home=centre
Dalal et al (2007)/
Taylor et al (2007)61
9 months MacNew Global
Score
5.61 (1.14) vs 5.54 (1.10) p=0.71 Home=centre
EQ-5D 0.74 (0.04) vs 0.78 (0.04) p=0.57 Home=centre
Jolly et al (2007) 6 months EQ-5D 0.74 (0.26) vs 0.76 (0.23) p=0.37 Home=centre
SF-12 PCS 42.28 (10.9) vs 42.56 (10.8) p=0.8 Home=centre
MCS 49.19 (10.1) vs 50.33 (9.6) p=0.3 Home=centre
12 months EQ-5D 0.74 (0.27) vs 0.76 (0.23) p=0.52* Home=centre
24 months EQ-5D 0.73 (0.29) vs 0.75 (0.26) p=0.39* Home=centre
Karapolat et al (2009) 8 weeks SF-36
Physical function 59.39 (25.35) vs 69.57 (20.94), p=0.08* Home=centre
Physical role 39.81 (41.75) vs 48.21 (45.10) p=0.43* Home=centre
Bodily pain 62.42 (30.45) vs 74.23 (19.66) p=0.07* Home=centre
General health 47.25 (23.42) vs 53.98 (25.00) p=0.33* Home=centre
Vitality 66.67 (19.82) vs 69.81 (17.41) p=0.49* Home=centre
Social function 65.33 (25.60) vs 69.33 (25.14) p=0.52* Home=centre
Emotional role 44.74 (39.77) vs 37.16 (39.24) p=0.44* Home=centre
Mental health 64.67 (19.04) vs 70.52 (20.37) p=0.22* Home=centre
Moholdt et al (2012) 6 months MacNew
Emotional domain 1.2 (0.2) vs 1.4 (0.2) p>0.05 Home=centre
Physical domain 1.4 (0.7) vs 1.6 (1.1) p>0.05 Home=centre
Social domain 4.3 (0.7) vs 4.3 (1.0) p>0.05 Home=centre
Oerkild et al (2011) 3 months SF-36 PCS 1.4 (−1.5 to 4.3) vs, 0.5 (−2.4 to 3.4), p>0.05 Home=centre
SF-36 MCS 0.8 (−2.6 to 4.3) vs −0.2 (−3.6 to 3.4), p>0.05 Home=centre
6 months SF-36 PCS 1.0 (−1.6 to 3.6) vs 1.2 (−1.4 to 3.8), p>0.05 Home=centre
SF-36 MCS 2.3 (−1.1 to 5.7) vs 2.6 (−0.9 to −6.0), p>0.05 Home=centre
Piotrowicz et al (2010) 8 weeks SF-36 total 70.5 (25.4) vs 69.2 (26.4) (p>0.05) Home=centre
*p Value calculated by authors of this report based on an independent two-group t-test.
Home=centre: no statistically significant difference (p≥0.05) in HRQoL between home-based and centre-based groups at follow-up.
Home>centre: statistically significant (p<0.05) higher HRQoL in home-based versus centre-based groups at follow-up.
Home<centre: statistically significant (p<0.05) lower HRQoL in home-based versus centre-based groups at follow-up.
HRQoL, health-related quality of life; MCS, mental component score; MLWHF, Minnesota Living With Heart Failure; NR, not reported; PCS,
physical component score; SF-12, 12-item Short Form Health Survey; SF-36, Short Form (36) Health Survey.
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and reduced level of hospitalisation) and was associated
with lower healthcare costs compared with an equivalent
clinic-based programme.45 46 Given this evidence for
disease management programmes, it has been proposed
that what matters may be the quality, structure and avail-
ability of the follow-up rather than the location of
follow-up per se.47
Despite level 1A evidence for the recommendation of
CR,10–15 the uptake of CR in the UK and internationally
remains suboptimal, with participation rates ranging
from 20% to 50%.7 20 48–50 Recent commentaries have
therefore called for alternative ways of providing CR to
improve participation.51 The choice of a home-based CR
intervention provides the opportunity to increase access
and uptake.34 52
The ﬁnding of this review of an absence of evidence
of important differences in patient outcomes and
healthcare costs between centre-based and home-based
CR supports the further provision of home-based CR
programmes. Self-management and collaboration with
caregivers can also improve uptake and outcomes.53–55
The main approach to CR delivery in most countries is
a supervised centre-based programme, which usually
takes place in a hospital, university or community
setting. However, the evidence of this review supports
national and international clinical guidelines for the
management of heart failure, explicitly recommending
home-based CR alongside more traditional supervised
centre-based CR programmes. The availability of home-
based programmes could increase participation in CR
by allowing those unable to attend centre-based CR ses-
sions due to problems involving access and lifestyle
commitments to take part in sessions that are individu-
ally tailored to suit their needs and ﬁt around their life.
This would overcome current capacity constraints
within centre-based programmes. Home-based pro-
grammes should, as centre-based, be comprehensive in
nature (ie, provide education and psychological
support in addition to exercise training) and include
health professional support such as regular telephone
calls and/or home visits, particularly in the early stages
of the programme. Providing patients with the choice
of centre-based or home-based CR (or a combination
of the two) according to their preferences may increase
both uptake and adherence. Patients recovering from
MI, coronary revascularisation and heart failure should
be able to beneﬁt from CR, which can prevent prema-
ture cardiovascular death, reduce hospital admissions
and improve HRQoL, something that has never been
accomplished for the majority of patients.8 56–59
Table 4 Summary of costs for home-based and centre-based groups
Trial
Author
(year)
Currency
Year of
costs
Follow-up
Cardiac
rehabilitation
programme cost
(per patient)
Programme
costs
considered
Total
healthcare
cost (per
patient)
Additional
healthcare costs
considered Comments
Carlson
et al (2000)
US$
Not
reported
6 months
Home: mean
1519
Centre: mean
2349
Staff, ECG
monitoring
Not reported
Marchionni
et al (2003)
US$
2000
14 months
Home: mean
1650
Centre: mean
8841
Not reported Home:
21 298
Centre:
13 246
Not reported
Dalal et al
2007
UK£
2002–
2003
9 months
Home: mean 170
(SD 8)
Centre: mean 200
(SD 3)
Difference: mean
30
95% CI −45 to
−12
p<0.0001
Staff, exercise
equipment, staff
travel
Home: mean
3279 (SD
374)
Centre: mean
3201 (SD
443)
Difference:
mean 78
95% CI
−1103 to
1191
p=0.894
Rehospitalisations,
revascularisations,
secondary
preventive
medication,
investigations,
primary care
consultations
Jolly et al
2007
UK£
2003
24 months
Home: mean 198
95% CI 189 to
209
Centre: mean 157
95% CI 139 to
175
p<0.05
Staff, telephone
consultations,
staff travel
Not reported With inclusion of patient
costs (travel and time),
the societal costs of
home-based and
centre-based cardiac
rehabilitation were not
significantly different.
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Table 5 Summary of healthcare resource use in home-based and centre-based cardiac rehabilitation by months of follow-up
Trial Author (year)
Dalal et al
(2007)
Gordon et al
(2002) Bell (1998)
Carlson et al
(2000)
Marchionni
et al (2003) Jolly et al (2007)
Moholdt et al
(2012) Oerkild et al (2011)
Follow-up 9 months 3 months 0–6 months 6–12 months 6 months 14 months 12 months 24 months 6 months 12 months
Rehospitalisations Not reported Number and length of
admissions same
between groups
N patient (%) Home 9/60
(15%)
Home 21/90
(23%)
13/89 (15%)
Centre 6/44
(14%)
Centre 19/88
(22%)
12/84 (14%)
p=0.845 p=0.78# p=0.95#
Mean (SD) Home 2.2
(0.9)†
Home 0.46
(SE 0.1)
Home 0.08 (0.34) Home 0.20 (0.45)
Centre 1.2
(0.6)
Centre 0.33
(SE 0.1)
Centre 0.12 (0.41) Centre 0.26 (0.57)
p=0.383 p=0.49 p=0.3 p=0.3
Primary care
consultations
Not reported Not reported
Mean (SD) Home 6.3
(0.6)
Home 6.6
(3.6)*
5.4 (4.1) Home 0.65 (1.14) Home 0.53 (1.14)
Centre 7.0
(0.9)
Centre 6.6
(4.1)
4.6 (3.7) Centre 0.72 (1.54) Centre 0.66 (1.42)
p=0.514 p=1.00# p=0.19# p=0.8 p=0.7
Secondary
prevention
medication
Not reported
N patients (%)
Beta-blockers
Home 31/49
(63%)
Home 36/97
(37%)
Home 19/38 Home 169 (72.2%) Home 161 (71.6%) Home: 8/14 (57%)
Centre 24/34
(71%)
Centre 17/45
(38%)
Centre 18/42 Centre 171 (73.4%) Centre 164 (72.2%) Centre: 15/16 (94%)
p=0.49 NS p=0.52# p=0.8 p=0.9 p=0.02*
ACE inhibitors Home 30/49
(61%)
Home 25/97
(26%)
Home 4/38 Home 176 (75.2%)* Home 177 (78.7%)* Home: 1/14 (7%)
Centre 24/33
(73%)
Centre 8/45
(18%)
Centre 4/42 Centre 161 (69.1%)* Centre 156 (68.7%)* Centre: 0/16 (0%)
p=0.28 NS p=0.88# p=0.1 p=0.02 p=0.28*
Statins Home 48/49
(98%)*
Home 73/97
(75%)
Home 5/38 Home 216 (92.3%)** Home 195 (86.7%)** Home: 6/14 (43%)
Centre 30/35
(88%)*
Centre 33/45
(73%)
Centre 8/42 Centre 221 (94.8%)** Centre 206 (90.7%)** Centre: 2/16 (13%)
p=0.18 NS p=0.47# p=0.3 p=0.2 p=0.07*
Antiplatelets Home 46/49
(94%)
Home 94/97
(97%)*
Home 15/38 Home 227 (97.0%)† Home 214 (95.1%)† Home: 14/14
(100%)
Centre 30/35
(86%)
Centre 45/45
(100%)*
Centre 20/42 Centre 226 (97.0%)† Centre 220 (96.9%)† Centre: 14/16
(100%)
p=0.21 NS p=0.54# p=1.0 p=0.3 p=0.18*
Comments †number of
nights
*lipid
lowering
drugs
*antiplatelets &
anticoagulants
NS: not
statistically
significant
*GP
consultations
#P-value calculated
by authors of the
present report
SE: standard
error
*angiotensin-converting-
enzyme inhibitor or
Angiotensin II receptor
antagonist
**cholesterol-lowering drugs
†Aspirin or antiplatelet
drugs
*angiotensin-converting-
enzyme inhibitor or
Angiotensin II receptor
antagonist
**cholesterol-lowering drugs
†Aspirin or antiplatelet
drugs
*p Value calculated
by authors of the
present report.
Figures are means (SD or 95% CI).
GP, general practitioner; NS, not statistically significant; SD, standard deviation.
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Limitations
The generally poor level of reporting in the included
studies made it difﬁcult to assess their methodological
quality and thereby judge their risk of bias. However, we
did ﬁnd some improvements in the quality of reporting
in recently published studies. Details of interventions
were often poorly reported, so it was also unclear
whether the CR programmes delivered in the included
studies meet the service quality recommendations such
as those of the UK CR standards.7 Our review is limited
by statistical heterogeneity in a number of outcomes
across trials, which may reﬂect the variety of centre-
based interventions. In addition, most studies were of
relatively short duration; only three trials reported out-
comes beyond 12 months of follow-up.32 36 38 Given the
variation in outcome measures across trials, we used the
SMD. This method assumes that differences in SDs
among studies reﬂect differences in measurement scales
and not real differences in variability of study popula-
tions.28 However, this assumption may be problematic in
the context of this systematic review where the study
populations vary in their indication.
Nevertheless, we believe this to be the most compre-
hensive review of evidence until now, summarising the
results of randomised trials in over 2000 patients.
CONCLUSIONS
Home-based and hospital-based or centre-based CR have
similar beneﬁts in terms of clinical events, risk factors
and HRQoL outcomes in patients after MI or coronary
revascularisation and in those with heart failure.
Together with the absence of evidence of differences in
healthcare costs, and given the current suboptimal
uptake of CR services, these ﬁndings strongly support
the further roll-out of home-based CR programmes,
thus offering patients improved access and choice.
Future research should focus on the long-term effects
of home-based versus centre-based CR, and well-
reported adequately powered head-to-head randomised
studies are needed in patient groups poorly represented
in this review, including angina pectoris.
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